Affymax Rises the Most Since 2006: San Francisco Mover

Affymax Inc. (AFFY) rose the most ever in New York trading, about 10 days after the drugmaker recalled its anemia treatment Omontys because of reports three people had fatal reactions to the medicine.

Affymax rose 54 percent to $3.52 at the close, the biggest one-day increase since the stock began trading publicly in December 2006. The shares of the Palo Alto, California-based company have dropped 67 percent in the past 12 months.

On Feb. 25, Affymax fell the most ever after recalling Omontys, which is used by kidney dialysis patients. Affymax and its partner Osaka, Japan-based Takeda Pharmaceutical Co. (4502) at the time said they were analyzing data from the three patients to find a cause for the reactions.

Sylvia Wheeler, a spokeswoman for the company, didn’t return telephone calls seeking comment.

To contact the reporter on this story: Elizabeth Lopatto in San Francisco at elopatto@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.